Navigation Links
BioMarin to Present at the Deutsche Bank Health Care Conference
Date:5/12/2009

NOVATO, Calif., May 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Deutsche Bank 34th Annual Health Care Conference in Boston on Tuesday, May 19, 2009 at 1:55 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                          Media
    Eugenia Shen                       Susan Berg
    BioMarin Pharmaceutical Inc.       BioMarin Pharmaceutical Inc.
    (415) 506-6570                     (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... ... ... LATHAM, NEW YORK... Marktech Optoelectronics will feature their new high-speed InGaAs ... Moscone Center from February 16-18, 2016, and at the healthcare-focused BiOS Expo on February ... standard packages feature a TO-46 metal can with active areas of 1.0mm and 1.5mm ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the world-leading ... and publication industries, will provide the data management solution ... (NPSC). ... Phenotypic analysis measures the ... organisms, allowing comparisons between states such as health and ...
(Date:1/22/2016)... http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced the ... in Retail Sector 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ...
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
Breaking Biology News(10 mins):